Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Melanoma vaccines: mixed past, promising future.

Literature DB >> 25245965

Melanoma vaccines: mixed past, promising future.

Junko Ozao-Choy¹, Delphine J Lee¹, Mark B Faries².

Abstract

Cancer vaccines were one of the earliest forms of immunotherapy to be investigated. Past attempts to vaccinate against cancer, including melanoma, have mixed results, showing the complexity of what was believed to be a simple concept. However, several recent successes and the combination of improved knowledge of tumor immunology and the advent of new immunomodulators make vaccination a promising strategy for the future.

Entities: Chemical Disease Gene Species

Keywords: Adjuvant; Immunomodulator; Immunotherapy; Melanoma; Vaccine

Mesh：

Substances：

Year: 2014 PMID： 25245965 PMCID： PMC4173123 DOI： 10.1016/j.suc.2014.07.005

Source DB: PubMed Journal: Surg Clin North Am ISSN： 0039-6109 Impact factor: 2.741

45 in total

1. Immune tolerance induced by intravenous transfer of immature dendritic cells via up-regulating numbers of suppressive IL-10(+) IFN-γ(+)-producing CD4(+) T cells.

Authors: Fang Zhou; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal: Immunol Res Date: 2013-05 Impact factor: 2.829

2. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.

Authors: Robert Dillman; Senthamil Selvan; Patric Schiltz; Cheryl Peterson; Kanoe Allen; Carol Depriest; Edward McClay; Neil Barth; Patric Sheehy; Cristina de Leon; Linda Beutel
Journal: Cancer Biother Radiopharm Date: 2004-10 Impact factor: 3.099

Review 3. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.

Authors: Giulio Tosti; Emilia Cocorocchio; Elisabetta Pennacchioli; Pier Francesco Ferrucci; Alessandro Testori; Chiara Martinoli
Journal: Expert Opin Biol Ther Date: 2014-03-26 Impact factor: 4.388

4. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

Authors: Jeffrey A Sosman; Joseph M Unger; P-Y Liu; Lawrence E Flaherty; Min S Park; Raymond A Kempf; John A Thompson; Paul I Terasaki; Vernon K Sondak
Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544

5. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

Authors: S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M Sznol; S L Schwarz; P J Spiess; J R Wunderlich; C A Seipp; J H Einhorn; L Rogers-Freezer; D E White
Journal: J Immunol Date: 1999-08-01 Impact factor: 5.422

Review 6. M-Vax: an autologous, hapten-modified vaccine for human cancer.

Authors: David Berd
Journal: Expert Rev Vaccines Date: 2004-10 Impact factor: 5.217

7. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.

Authors: Travis B Kidner; Donald L Morton; Delphine J Lee; Mary Hoban; Leland J Foshag; Roderick R Turner; Mark B Faries
Journal: J Immunother Date: 2012 Nov-Dec Impact factor: 4.456

8. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.

Authors: M J Mastrangelo; R E Bellet; J Berkelhammer; W H Clark
Journal: Cancer Date: 1975-10 Impact factor: 6.860

Melanoma vaccines: mixed past, promising future.

1. Immune tolerance induced by intravenous transfer of immature dendritic cells via up-regulating numbers of suppressive IL-10(+) IFN-γ(+)-producing CD4(+) T cells.

2. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.

Review 3. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.

4. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

5. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

Review 6. M-Vax: an autologous, hapten-modified vaccine for human cancer.

7. Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma.

8. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.

9. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

10. Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.

Review 1. Immunotherapy of Melanoma: Facts and Hopes.

2. An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

3. Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine.

Review 4. Advances in immunotherapy for melanoma management.

Review 5. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

6. The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia.

Review 7. Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines.

8. Immuno-oncology combinations: raising the tail of the survival curve.

Review 9. Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers.

Review 10. B4GALNT2 and xenotransplantation: A newly appreciated xenogeneic antigen.